Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Should You Still Buy the Nasdaq's Best-Performing September Stocks?
06:53am, Tuesday, 10'th Oct 2023
Global Foundries could benefit from AI-driven demand for chips. Amgen has some weight-loss drugs in the pipeline that could boost the bottom line.
2 Magnificent Dividend Stocks to Buy Hand Over Fist in October
10:15am, Monday, 09'th Oct 2023
With bond yields near historic highs in many instances, stock prices have softened at the onset of Q4. Even so, dividend stocks are still likely to outperform most other asset classes in both the shor
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
07:32pm, Friday, 06'th Oct 2023
Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
10:31am, Friday, 06'th Oct 2023
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen completes $27.8 bln Horizon deal
09:18am, Friday, 06'th Oct 2023
Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions
Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel votes against it
08:36am, Friday, 06'th Oct 2023
Amgen Inc. said it would continue to work closely with the Food and Drug Administration to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer, after an advisory p
US FDA panel gives thumbs down on approval for Amgen lung cancer drug
02:49pm, Thursday, 05'th Oct 2023
Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial was not reliable enough to support traditional approval of Amgen's Lumakras for patients with a ty
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
09:43am, Tuesday, 03'rd Oct 2023
The U.S. Food and Drug Administration's staff reviewers said on Tuesday that Amgen's late-stage study may not provide enough evidence of effectiveness for its lung cancer drug, as the company pursues
Jim Cramer looks at Amgen's stellar performance in Q3
08:12pm, Monday, 02'nd Oct 2023
'Mad Money' host Jim Cramer takes a look back at the third quarter of the year.
Drugmakers opt in to Medicare drug price negotiations – here's what happens next
03:34pm, Monday, 02'nd Oct 2023
The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
Drugmakers sign on to negotiate Medicare prices under protest
01:02pm, Monday, 02'nd Oct 2023
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part
Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not.
01:34pm, Friday, 29'th Sep 2023
Amgen was the best-performing stock in both the Dow Jones Industrial Average and Nasdaq 100 in the third quarter, while Zions Bancorp, up 32%, was the top stock in the S&P 500.
3 Stocks to Focus on as Demand for Obesity Drugs Booms
11:17am, Friday, 29'th Sep 2023
The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's N
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
08:45am, Thursday, 28'th Sep 2023
The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
08:36am, Wednesday, 27'th Sep 2023
Amgen Inc.'s disclosure Wednesday of a large stake in Neumora Therapeutics Inc. indicates that the value of its investment in the biopharmaceutical company, which recently went public, has tripled.
